In a surprise move Thursday, Neumora remade its executive team and brought back its former CEO, following last month's ...

Sanofi faces $250M charge after E. coli vaccine developed with J&J fails Phase 3 trial; study ends early due to insufficient ...

An NIH cap on indirect cost payments for grant recipients is casting a shroud of uncertainty for research universities ...

New re­search from the Uni­ver­si­ty of North Car­oli­na-Chapel Hill found that No­vo Nordisk’s weight loss drug may help ...

Pfizer secured an eighth indication for its blood cancer drug Adcetris after the FDA approved its use in adults, in ...

CVS Health ended 2024 as it started, with high medical costs in the company’s insurance business chipping away at its bottom ...

Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, further demonstrating that the pharma-to-startup pipeline for CNS drugs is ...

AnaptysBio trumpeted a Phase 2b success in rheumatoid arthritis Wednesday morning after a similar program from Eli Lilly was discontinued late last year.

Ab­b­Vie and Xilio Ther­a­peu­tics are part­ner­ing to make “masked” T cell en­gagers, which they hope will be safer than cur­rent­ly avail­able op­tions.

Aardvark Therapeutics will debut on Nasdaq at $16/share, to raise $94M for hunger-focused metabolic disease treatments. ARD-101 Phase 3 data expected early 2025.